Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Jill Corre, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Thierry Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chrétien, Sophie Godet, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Jean Pierre Marolleau, Pascal Godmer, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Amine Kasmi, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Cyrille Hulin, Xavier Leleu

Blood (2024) 144 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2024-210345

Published: 2024

Journal Articles

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Blood (2023) 142 (Supplement 1): 7443.

https://doi.org/10.1182/blood-2023-182117

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry

Blood (2023) 142 (Supplement 1): 6471.

https://doi.org/10.1182/blood-2023-177787

Published: 2023

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Blood (2023) 142 (Supplement 1): 6724.

https://doi.org/10.1182/blood-2023-186599

Published: 2023

Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Blood (2023) 142 (Supplement 1): 6741.

https://doi.org/10.1182/blood-2023-185699

Published: 2023

Journal Articles

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Blood (2022) 140 (Supplement 1): 4423–4425.

https://doi.org/10.1182/blood-2022-168742

Published: 2022

Journal Articles

Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study

Laure Vincent, Anne Charvet-Rumpler, Lotfi Benboubker, Claire Calmettes, Anne-Marie Stoppa, Kamel Laribi, Lauriane Clement Filliatre, Fressia Honeyman, Richez Valentine, Cyrille Hulin, Frédéric Maloisel, Margaret Macro, Lionel Karlin, Vanessa Barué, Christos Chouaid, Hacène Zerazhi, Xavier Leleu

Blood (2022) 140 (Supplement 1): 4312–4314.

https://doi.org/10.1182/blood-2022-157942

Published: 2022

Journal Articles

Feasibility and Outcome of Late Intensification with Native L-Asparaginase for Acute Lymphoblastic Leukemia in the Elderly: A Single Center Experience

Francois Xavier Gros, MD, Pierre-Yves Dumas, MD, Edouard Forcade, MD, Claire Calmettes, MD, Margot Robles, MD, Vincent Servant, PharmD, Nicolas Lechevalier, PharmD, Audrey Bidet, PharmD, Noel Milpied, Arnaud Pigneux, MD PhD, Thibaut Leguay, MD

Blood (2017) 130 (Supplement 1): 1296.

https://doi.org/10.1182/blood.V130.Suppl_1.1296.1296

Published: 2017

Journal Articles

Improved Outcome with a Pediatric-Inspired Regimen for Philadelphia-Negative Acute Lymphoblastic Leukemia in the Elderly

Blood (2017) 130 (Supplement 1): 2560.

https://doi.org/10.1182/blood.V130.Suppl_1.2560.2560

Published: 2017

Journal Articles

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Blood (2015) 126 (23): 5108.

https://doi.org/10.1182/blood.V126.23.5108.5108

Published: 2015

Journal Articles

Impact Of Female Donor On Allogeneic Stem Cell Transplantation Outcome Of Male Recipient After T-Cell Depletion By Rabbit Antithymocyte Globulin

Claire Calmettes, Stephane Vigouroux, MD, Reza Tabrizi, MD, Arnaud Pigneux, MD, PhD, Thibaut Leguay, MD, Krimo Bouabdallah, MD, Marie-Sarah Dilhuydy, MD, Cedric Duclos, MD, Axelle Lascaux, MD, Pierre-Yves Dumas, MD, Sophie Dimicoli-Salazar, MD, Gerald Marit, MD, Noel Milpied, MD, PhD

Blood (2013) 122 (21): 5477.

https://doi.org/10.1182/blood.V122.21.5477.5477

Published: 2013

Journal Articles

Risk Factors For Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation From Matched Related Or Unrelated Donors

Blood (2013) 122 (21): 4595.

https://doi.org/10.1182/blood.V122.21.4595.4595

Published: 2013

Journal Articles

Romiplostim (AMG531, Nplate ® ) for Secondary Failure of Platelet Recovery After Allogeneic Stem-Cell Transplantation

Claire Calmettes, Stephane Vigouroux, Reza Tabrizi, MD, Noel Milpied, MD

Blood (2011) 118 (21): 1994.

https://doi.org/10.1182/blood.V118.21.1994.1994

Published: 2011

NARROW

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry

Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study

Feasibility and Outcome of Late Intensification with Native L-Asparaginase for Acute Lymphoblastic Leukemia in the Elderly: A Single Center Experience

Improved Outcome with a Pediatric-Inspired Regimen for Philadelphia-Negative Acute Lymphoblastic Leukemia in the Elderly

Yttrium-90 Ibritumomab Tiuxetan Is Feasible and Efficient in Unselected Patients. Definitive Results of a Large Retrospective Phase IV Study

Impact Of Female Donor On Allogeneic Stem Cell Transplantation Outcome Of Male Recipient After T-Cell Depletion By Rabbit Antithymocyte Globulin

Risk Factors For Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation From Matched Related Or Unrelated Donors

Romiplostim (AMG531, Nplate ® ) for Secondary Failure of Platelet Recovery After Allogeneic Stem-Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only